Pinned post
U01 Funded!!! Up to 20% of MS diagnoses turn out to be inaccurate. Our new multicenter NAIMS study aims to validate a new diagnostic biomarker. #CleClinicNeuro @CleClinicMD @danielsaloreich @CedarsSinai @satipascal consultqd.clevelandclinic.org/central-vein-s…
consultqd.clevelandclinic.org Central Vein Sign: Large Study Is Launched to Establish a New Diagnostic Biomarker in MS Up to 20% of multiple sclerosis diagnoses turn out to be inaccurate. A new multicenter study aims to reduce that number by bringing this new biomarker into the diagnostic mix.